350684-49-0

Usage

Uses

Used in Pharmaceutical Research and Development:
TERT-BUTYL 4-(4-AMINOBENZOYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is used as a potential drug candidate for its ability to target various diseases and medical conditions. Its unique structure and functional groups contribute to its potential therapeutic effects, making it a valuable asset in the search for new treatments.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, TERT-BUTYL 4-(4-AMINOBENZOYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is utilized for its potential to interact with biological targets, such as enzymes or receptors, to modulate their activity. This interaction can lead to the development of new drugs with improved efficacy and selectivity.
Used in Drug Design and Optimization:
TERT-BUTYL 4-(4-AMINOBENZOYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE serves as a starting point for drug design and optimization processes. Its structural features can be modified to enhance its pharmacological properties, such as potency, selectivity, and bioavailability, ultimately leading to the development of more effective therapeutic agents.
Used in Preclinical and Clinical Studies:
As a potential drug candidate, TERT-BUTYL 4-(4-AMINOBENZOYL)TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE is subjected to preclinical and clinical studies to evaluate its safety, efficacy, and pharmacokinetic properties. These studies are crucial for determining its suitability as a therapeutic agent and guiding further development efforts.

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 
• 509073-62-5 tert-butyl 4-(4-nitrobenzoyl)piperazine- 1-carboxylate 

Downstream Products

• 700804-69-9 N-cyano-N'-((4-(4-tert-butoxycarbonyl)piperazinocarbonyl)-phenyl)-O-phenylisourea 
• 1235467-40-9 tert-butyl 4-(4-(4-bromo-2-cyanophenylamino)-benzoyl)piperazine-1-carboxylate 
• 1566583-85-4 2-(2-(2-(2-((4-(piperazine-1-carbonyl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)ethyl)phenyl)acetamide 
• 1566584-52-8 tert-butyl 4-(4-((4-(2-(2-amino-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzoyl)piperazine-1-carboxylate 
• 1566584-51-7 C₃₁H₃₄F₃N₅O₅ 
• 1566584-50-6 tert-butyl 4-(4-((4-(2-(2-methoxy-2-oxoethyl)phenethyl)-5-(trifluoromethyl)pyrimidin-2-yl)amino)benzoyl)piperazine-1-carboxylate 

Relevant academic research and scientific papers

Memantine urea derivative as well as preparation method and application thereof

The invention provides a memantine urea derivative as well as a preparation method and application thereof, and relates to the technical field of medicines. The memantine urea derivative provided by the invention has a typical urea structure as a primary

CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS

This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.

SMALL MOLECULE PROTEOLYSIS-TARGETING CHIMERAS AND METHODS OF USE THEREOF

Novel small molecule proteolysis-targeting chimeras (PROTACs) are provided, along with methods for their use as Bruton's tyrosine kinase (BTK) degraders. The small molecule PROTACs described herein are useful in treating and/or preventing BTK-related diseases, such as cancer, neurodegenerative disorders, inflammatory diseases, and metabolic disorders. Also provided are methods for inducing BTK degradation in a cell using the compounds and compositions described herein. Exemplary compounds include: (I).

Aminodithioformate compound used as FAK inhibitor

A purpose of the invention is to provide an aminodithioformate compound serving as an FAK inhibitor, a pharmaceutical composition, a preparation method and applications thereof, wherein the compound has a structure represented by the following general formula (I).

Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities

A series of 2,4-diarylaminopyrimidine derivatives containing dithiocarbamate moiety were designed by molecular hybridization strategy and synthesized for screening as inhibitors of focal adhesion kinase (FAK). Most of these compounds exhibit significant a

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

The present application provides bifunctional compounds of Formula X or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

The present application provides bifunctional compounds of Formula (I), or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

The present application provides bifunctional compounds of Formula (X), or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for Bruton's tyrosine kinase (BTK). The present application also relates to methods for the targeted degradation of BTK through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to BTK which can be utilized in the treatment of disorders modulated by BTK.

Piperazine substituted 1, 3 - di-substituted urea compound and piperazine substituted amide compounds and a method for its preparation and use

The present invention relates to a class of piperazine substituted 1,3-disubstitued urea compounds and piperazine substituted amide compounds, or pharmaceutically acceptable salts of the piperazine substituted 1,3-disubstitued urea compounds and the piper

VEGFR3 INHIBITORS

This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.